Gene Therapy Casgevy denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for gene therapy casgevy are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Casgevy as Non-Formulary

UnitedHealthcare's formulary is a curated list of covered drugs. Casgevy, as a gene therapy administered once in a specialized center, is not a standard pharmacy formulary item and is typically covered (if at all) under the medical benefit rather than the pharmacy benefit. A non-formulary denial often reflects a benefit-routing issue — the claim was submitted under the pharmacy benefit when it should be evaluated under the medical benefit — or a missing formulary exception request. Identifying which situation applies is the first step.

## Why This Denial Is Appealable

For plans subject to the ACA, formulary exceptions are available when no formulary alternative is clinically appropriate. For ERISA plans, §503 requires a full-and-fair review of any adverse benefit determination. Because no formulary drug replicates the curative mechanism of a gene therapy, the formulary-exception argument is particularly strong. Additionally, if the denial reflects a wrong benefit classification (pharmacy vs. medical), the fix may be administrative rather than clinical.

## Federal Appeal Framework

• Benefit clarification (pre-appeal): Call UHC member services and ask whether Casgevy is covered under the medical benefit rather than the pharmacy benefit. If so, resubmitting under the correct benefit category may resolve the denial without a formal appeal.
• Formulary exception request / internal appeal: File simultaneously. Request UHC's formulary exception form and submit it with your clinical documentation.
• External review: If denied after internal appeal, request IRO review within approximately four months of the final denial.
• Expedited review: Available when treatment timing is clinically urgent.

## Documentation to Gather

1. Benefit classification check: Obtain in writing from UHC whether Casgevy falls under the pharmacy or medical benefit for your specific plan. 2. No formulary equivalent: A letter from your hematologist stating that no drug on UHC's formulary provides a clinically equivalent alternative for your specific condition. 3. FDA prescribing label: Confirming that the prescribed use is the FDA-approved on-label indication. 4. Diagnosis and severity records: Chart documentation supporting medical necessity for Casgevy specifically. 5. Prior treatment documentation: Records of prior disease-modifying therapies and outcomes, demonstrating that formulary alternatives have been inadequate.

## Criteria-Mapping Strategy

Obtain UHC's formulary exception criteria from your plan documents or member services. For each criterion, identify the clinical document that satisfies it. The core argument is three-part: (1) Casgevy is FDA-approved for your exact diagnosis; (2) no formulary drug is therapeutically equivalent; and (3) your clinical history supports medical necessity under both the FDA label and UHC's own coverage policy. Present this as a concise numbered response to each stated denial reason, with labeled supporting exhibits.